TG Therapeutics
ShareCopied to clipboardTG Therapeutics is a company. It is a public company in Morrisville, the United States. It was founded in 1993 and its current CEO is Michael S. Weiss. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Morrisville
- country: United States
- employees: 338 people
- revenues: 264.8M $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 1993
- CEO: Michael S. Weiss
- ESG score: 69.43 / 100
See more facts
Extract data
Download datasets about TG Therapeutics:
Dataset of stocks from TG Therapeutics:
TG Therapeutics is one of the companies in the United States, companies in Biotechnology, companies in Health Care, companies in Morrisville and 3,456,808 companies in our database.
Talking Points
- HomeTG Therapeutics
- TG is a biopharmaceutical company focused on the acquisition, development & commercialization of treatments for B-cell diseases.
- TG is a commercial stage biopharmaceutical company focused on the development of novel treatments for B-cell diseases. | TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.